---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026971"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:18:25.968121+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Reviva Q2 2025 net loss $6.1M ($0.12/share); cash $10.4M; brilaroxazine OLE data positive

## Summary
- Net loss $6.1M vs $7.9M YoY; cash $10.4M as of June 30, 2025, down from $13.5M at Dec 2024.
- Completed Phase 3 RECOVER OLE 1-year trial: brilaroxazine sustained PANSS total score -18.1 over 1 year.
- FDA meeting planned Q4 2025 for path to approval; potential NDA submission targeted Q2 2026.
- Completed $10.0M public equity offering in Q2 2025.
- Plans to assess registrational Phase 3 RECOVER-2 pending FDA feedback; IND for psoriasis formulation expected Q2 2026.

## SEC filing metadata
- accession: 0001437749-25-026971
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/0001437749-25-026971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774925026971/rvph20250805_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026971
- JSON: https://secwatch.observer/filing/0001437749-25-026971.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.